Surgical sealant to be assessed in Europe:
This article was originally published in Clinica
Executive Summary
Cohesion Technologies of Palo Alto, California, has begun a European feasibility study to assess its new product for preventing blood leaks in cardiovascular and vascular surgery. CoSeal surgical sealant, a totally synthetic gel which polymerises at the surgical site in seconds, takes about five minutes to prepare and completely resorbs within 30 days. The product will be tested in up to 15 patients undergoing peripheral vascular surgery. Palo Alto-based Cohesion's first product, CoStasis, a surgical haemostat to treat diffuse bleeding, is already available in certain European countries and is expected to be submitted for US marketing approval by spring 1999.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.